ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinibmaleat - mittel gegen dermatitis, ausgenommen corticosteroide - hunde - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

bavarian nordic a/s - modifizierte vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - andere virale impfstoffe, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 und 5. der einsatz dieses impfstoffs sollte in übereinstimmung mit den offiziellen empfehlungen.

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

virbac s.a. - hydrocortisonaceponat - corticosteroide, dermatologische präparate - hunde - zur symptomatischen behandlung von entzündlichen und juckenden dermatosen bei hunden. for alleviation of clinical signs associated with atopic dermatitis in dogs.

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

জার্মানি - জার্মান - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

almirall hermal gmbh (3079083) - mometasonfuroat (ph.eur.) - salbe - teil 1 - salbe; mometasonfuroat (ph.eur.) (24367) 1 milligramm

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

জার্মানি - জার্মান - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

harras pharma curarina arzneimittel gmbh arzneimittelforschung und -vertrieb (3264337) - levomenol; heparin-natrium ((mit angaben zur herkunft)) - creme - levomenol (18369) 0,3 gramm; heparin-natrium ((mit angaben zur herkunft)) (01165) 20000 internationale einheit

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopisch - andere dermatologische präparate - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopisch - andere dermatologische präparate - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.